Melanoma
1,462
187
307
685
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
327 trials with published results (22%)
Research Maturity
685 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.9%
232 terminated out of 1462 trials
74.7%
-11.8% vs benchmark
6%
87 trials in Phase 3/4
48%
327 of 685 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 685 completed trials
Clinical Trials (1462)
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Natural History Study of Early Life Exposures in Agriculture (ELEA)
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Clinical Genetics Branch Eligibility Screening Survey
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Axitinib + Ipilimumab in Advanced Melanoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
A Study of IBI363 in Subjects With Advanced Melanoma
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors